Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie's RINVOQ (upadacitinib) has received FDA approval as the first oral JAK inhibitor for treating giant cell arteritis (GCA) in adults. This marks RINVOQ's ninth approved indication in the U.S., following recent European Commission authorization.
The approval is based on the Phase 3 SELECT-GCA trial results, where 46.4% of patients using RINVOQ 15mg with a 26-week steroid taper achieved sustained remission, compared to 29% in the placebo group. The drug's safety profile remained consistent with previous indications.
GCA is an autoimmune disease affecting cranial arteries, primarily impacting Caucasian women over 50. If untreated, it can lead to severe outcomes including blindness and stroke. RINVOQ offers an alternative to traditional steroid treatment, though it may cause serious side effects including infections, blood clots, and increased risk of major cardiovascular events in certain patients.
AbbVie (ABBV) reported strong Q1 2025 financial results with worldwide net revenues of $13.343 billion, up 8.4% on a reported basis. The company's immunology portfolio led growth with revenues of $6.264 billion (+16.6%), driven by Skyrizi ($3.425 billion, +70.5%) and Rinvoq ($1.718 billion, +57.2%). Neuroscience portfolio revenues increased 16.1% to $2.282 billion.
Q1 diluted EPS was $0.72 on a GAAP basis (-6.5%) and adjusted diluted EPS was $2.46 (+6.5%). The company raised its 2025 adjusted diluted EPS guidance from $11.99-$12.19 to $12.09-$12.29. Notable developments include FDA approval of Emblaveo for complicated intra-abdominal infections and entrance into the obesity treatment field through a partnership with Gubra.
AbbVie (NYSE: ABBV) has submitted a Biologics License Application (BLA) to the FDA for TrenibotulinumtoxinE (TrenibotE), a first-in-class botulinum neurotoxin for treating moderate to severe glabellar lines. The key differentiator of TrenibotE is its rapid onset of action within 8 hours and shorter duration of 2-3 weeks.
The submission is backed by clinical data from over 2,100 patients across multiple Phase 3 studies. All primary and secondary endpoints were met, with treatment-emergent adverse events similar to placebo. If approved, TrenibotE will be the first serotype E neurotoxin available, offering patients a shorter-duration alternative to traditional treatments.
The product aims to address patient concerns about 'fear of looking unnatural' by providing a shorter-term trial option before committing to longer-lasting treatments like BOTOX® Cosmetic.
AbbVie (NYSE: ABBV) has received European Commission approval for RINVOQ® (upadacitinib) to treat adult patients with giant cell arteritis (GCA). This marks RINVOQ's eighth approved indication in the EU.
Key highlights from the Phase 3 SELECT-GCA trial:
- 46.4% of patients using RINVOQ 15mg achieved sustained remission at week 52, compared to 29.0% in the placebo group
- Disease flares were reduced to 34.3% in the RINVOQ group versus 55.6% in placebo
- Lower cumulative steroid exposure was achieved (1615mg vs 2882mg median)
- 37.1% of RINVOQ patients achieved sustained complete remission versus 16.1% in placebo
The safety profile remained consistent with previously approved indications, with comparable rates of serious adverse events between RINVOQ and placebo groups. RINVOQ is the first and only oral JAK inhibitor approved in the EU for GCA treatment.
AbbVie (NYSE: ABBV) has scheduled its first-quarter 2025 financial results announcement for Friday, April 25, 2025, before market opening. The company will host a live webcast earnings conference call at 8 a.m. Central time, which will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived version of the session will be made available later the same day.
AbbVie (NYSE: ABBV) announced new data presentations at the upcoming AACR Annual Meeting (April 25-30, 2025), highlighting advances in early oncology research. The company will showcase two key investigational molecules:
1. ABBV-969: A novel dual-targeted antibody-drug conjugate (ADC) targeting STEAP1/PSMA in Phase 1 trials for metastatic castration-resistant prostate cancer. The drug uses a proprietary cytotoxic topoisomerase 1 inhibitor payload.
2. ABBV-514: A novel CCR8-targeting antibody in Phase 1 trials for non-small cell lung cancer, head and neck cancer, and other solid tumors. Preclinical data shows strong monotherapy activity, including in anti-PD-1 resistant models.
Additional presentations will focus on real-world-data analyses regarding treatment resistance and biomarker identification, including studies on folate receptor alpha expression in ovarian cancers and immunotherapy response in non-small cell lung cancer.
Allergan Aesthetics, an AbbVie company, will showcase its innovation and expertise at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from March 27-29, 2025. The event will highlight the new AA Signature program, an innovative treatment planning approach, and celebrate 10 years of MD Codes™.
The congress features four expert-led educational events through the Allergan Medical Institute (AMI), including two major symposia: 'Design your patients' look with the NEW Signature approach' and a special session celebrating MD Codes™' decade of excellence. The program includes live injection sessions and a fireside chat with Dr. Maurício de Maio.
Additional highlights include the Science of Aging™ Symposium focusing on scientific advances in aging, and a Global Aesthetics Medical Affairs Symposium exploring the impact of aesthetic medicine on emotional well-being. The event will also feature eleven E-Poster presentations and Meet the Expert sessions at the Allergan Aesthetics booth.
AbbVie (ABBV) announced final analysis results from the Phase 3 MIRASOL trial for ELAHERE® in treating folate receptor alpha-positive platinum-resistant ovarian cancer. After 30.5 months median follow-up, the drug showed:
- 32% reduction in death risk compared to chemotherapy
- Median progression-free survival of 5.59 months vs 3.98 months for chemotherapy
- 41.9% objective response rate vs 15.9% for chemotherapy
- Median overall survival of 16.85 months vs 13.34 months for chemotherapy
The study included 453 patients with high-grade serous epithelial PROC. Common side effects included blurred vision, keratopathy, and abdominal pain, with lower rates of serious adverse events compared to chemotherapy. ELAHERE received full FDA approval in March 2024 and European Commission approval in November 2024.
AbbVie (NYSE: ABBV) has announced its upcoming participation in the Leerink Partners Global Healthcare Conference scheduled for Tuesday, March 11, 2025. The company's management team will engage in a fireside chat presentation starting at 7:40 a.m. Central time.
Investors and interested parties can access a live audio webcast of the presentation through AbbVie's Investor Relations website at investors.abbvie.com. For those unable to attend the live session, an archived version will be made available on the same day.
AbbVie (NYSE: ABBV) and Gubra A/S have announced a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for obesity treatment. This partnership marks AbbVie's strategic entry into the obesity market.
The agreement includes a $350 million upfront payment to Gubra, with potential additional payments of up to $1.875 billion in development, commercial, and sales milestones, plus tiered royalties on global net sales. AbbVie will lead global development and commercialization activities.
GUB014295, currently in Phase 1 clinical trials, is an agonist that activates amylin and calcitonin receptors. The compound works by triggering appetite suppression signals to the brain, reducing food intake, and delaying gastric emptying. This development addresses a significant global health concern, with approximately 900 million adults affected by obesity.